Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis

Medical Clinics of North America

Volumn 97, Issue 3, 2013, Pages 377-398

  Rowe, Christopher C ^a   Villemagne, Victor L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

A levels; Alzheimer disease; Amyloid imaging; Posistron emission tomography

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CARBON 11; FLORBETABEN; FLUORINE 18; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPSY; BINDING AFFINITY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DELAYED DIAGNOSIS; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EPISODIC MEMORY; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC RISK; GLUCOSE METABOLISM; HUMAN; LIPOPHILICITY; MEMORY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSEUDODEMENTIA; REVIEW; SIGNAL NOISE RATIO; WORKING MEMORY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ASYMPTOMATIC DISEASES; BRAIN; CARBON RADIOISOTOPES; CHROMOSOME ABERRATIONS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FLUORINE RADIOISOTOPES; HETEROZYGOTE DETECTION; HUMANS; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; STATISTICS AS TOPIC; THIAZOLES;

EID: 84877022699     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.12.017     Document Type: Review

References (165)

1. Masters C.L., Cappai R., Barnham K.J., et al. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006, 97:1700-1725.
2. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch Neurol 1985, 42:1097-1105.
3. Jellinger K. Morphology of Alzheimer disease and related disorders. Alzheimer disease: epidemiology, neuropathology, neurochemistry, and clinics 1990, 61-77. Springer-Verlag, Berlin. K. Maurer (Ed.).
4. Masters C.L., Beyreuther K. The neuropathology of Alzheimer's disease in the year 2005. Neurodegenerative diseases: neurobiology, pathogenesis and therapeutics 2005, 433-440. Cambridge University Press, Cambridge (England). M.F. Beal (Ed.).
5. Jellinger K.A., Bancher C. Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 1998, 54:77-95.
6. Masters C.L., Simms G., Weinman N.A., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82:4245-4249.
7. Cappai R., White A.R. Amyloid beta. Int J Biochem Cell Biol 1999, 31:885-889.
8. Villemagne V.L., Cappai R., Barnham K.J., et al. The Aβ centric pathway of Alzheimer's disease. Abeta peptide and Alzheimer's Disease 2006, 5-32. Springer-Verlag, London. C.J. Barrow, B.J. Small (Eds.).
9. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997, 20:154-159.
10. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
11. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: Diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
12. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
13. Clark C.M., Davatzikos C., Borthakur A., et al. Biomarkers for early detection of Alzheimer pathology. Neurosignals 2008, 16:11-18.
14. Jack C.R., Knopman D.S., Jagust W.J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
15. de Leon M.J., Convit A., DeSanti S., et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int Psychogeriatr 1997, 9:183-190. [discussion: 247-52].
16. Xu Y., Jack C.R., O'Brien P.C., et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000, 54:1760-1767.
17. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
18. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
19. Rowe C.C., Ng S., Ackermann U., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
20. Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000, 15:93-101.
21. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
22. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
23. Albert M.S., Dekosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
24. Petersen R.C. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007, 27:22-31.
25. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000, 41:661-681.
26. Mathis C.A., Klunk W.E., Price J.C., et al. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 2005, 62:196-200.
27. Villemagne V.L., Rowe C.C., Macfarlane S., et al. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci 2005, 12:221-230.
28. Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003, 5:363-375.
29. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004, 3:519-527.
30. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30:431-440.
31. Villemagne V.L., Rowe C.C. Amyloid ligands for dementia. PET Clin 2010, 5:33-53.
32. Shoghi-Jadid K., Small G.W., Agdeppa E.D., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
33. Rowe C.C., Ackerman U., Browne W., et al. Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
34. Serdons K., Terwinghe C., Vermaelen P., et al. Synthesis and evaluation of (18)F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease. J Med Chem 2009, 52:1428-1437.
35. Wong D.F., Rosenberg P.B., Zhou Y., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010, 51:913-920.
36. Cselenyi Z., Jonhagen M.E., Forsberg A., et al. Clinical Validation of 18F-AZD4694, an Amyloid-beta-Specific PET Radioligand. J Nucl Med 2012, 53:415-424.
37. Cohen A.D., Rabinovici G.D., Mathis C.A., et al. Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 2012, 64:27-81.
38. Price J.C., Klunk W.E., Lopresti B.J., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005, 25:1528-1547.
39. Maeda J., Ji B., Irie T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007, 27:10957-10968.
40. Fodero-Tavoletti M.T., Rowe C.C., McLean C.A., et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med 2009, 50:198-204.
41. Lockhart A., Lamb J.R., Osredkar T., et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130:2607-2615.
42. Maezawa I., Hong H.S., Liu R., et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 2008, 104:457-468.
43. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007, 27:10365-10371.
44. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
45. Mintun M.A., Larossa G.N., Sheline Y.I., et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
46. Ng S.Y., Villemagne V.L., Masters C.L., et al. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 2007, 64:1140-1144.
47. Rabinovici G.D., Furst A.J., O'Neil J.P., et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
48. Clark C.M., Schneider J.A., Bedell B.J., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283.
49. Barthel H., Gertz H.J., Dresel S., et al. Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435.
50. Villemagne V.L., Ong K., Mulligan R.S., et al. Amyloid Imaging with 18F-Florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52:1210-1217.
51. Nelissen N., Van Laere K., Thurfjell L., et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009, 50:1251-1259.
52. Vandenberghe R., Van Laere K., Ivanoiu A., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010, 68:319-329.
53. Tolboom N., Yaqub M., van der Flier W.M., et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009, 50:191-197.
54. Ossenkoppele R., Tolboom N., Foster-Dingley J.C., et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012, 39:990-1000.
55. Zhang W., Oya S., Kung M.P., et al. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 2005, 48:5980-5988.
56. Ong K., Villemagne V.L., Lamngon N., et al. Assessment of Aβ Deposition in Mild Cognitive Impairment with 18F-Florbetaben. Alzheimers Dement 2010, 6:S26.
57. Villemagne V.L., Mulligan R.S., Pejoska S., et al. Comparison of (11)C-PiB and (18)F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012, 39:983-989.
58. Zhang W., Oya S., Kung M.P., et al. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 2005, 32:799-809.
59. Clark C.M., Pontecorvo M.J., Beach T.G., et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678.
60. Wolk D.A., Zhang Z., Boudhar S., et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012, 83:923-926.
61. Landau S.M., Breault C., Joshi A.D., et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2012, 10.2967/jnumed.112.109009.
62. Serdons K., Verduyckt T., Vanderghinste D., et al. Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. Bioorg Med Chem Lett 2009, 19:602-605.
63. Buckley C., Ikonomovic M., Smith A., et al. Flutemetamol F 18 injection PET images reflect brain beta-amyloid levels. Alzheimers Dement 2012, 8:P90.
64. Thurfjell L., Lotjonen J., Lundqvist R., et al. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis 2012, 10:246-249.
65. Duara R., Loewenstein D.A., Shen Q., et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 2012, [Epub ahead of print].
66. Vandenberghe R., Nelissen N., Salmon E., et al. Binary classification of (18)F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. Neuroimage 2013, 64:517-525.
67. Wolk D.A., Grachev I.D., Buckley C., et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011, 68:1398-1403.
68. Wong D.F., Moghekar A.R., Rigamonti D., et al. An in vivo evaluation of cerebral cortical amyloid with [(18)F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 2012, [Epub ahead of print].
69. Rowe C.C., Villemagne V.L. Brain amyloid imaging. J Nucl Med 2011, 52:1733-1740.
70. Rowe C.C., Pejoska S., Mulligan R.S., et al. Head to head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in ageing and dementia. J Nucl Med 2013, [in press].
71. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
72. Buckner R.L., Snyder A.Z., Shannon B.J., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005, 25:7709-7717.
73. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008, 1124:1-38.
74. Drzezga A., Becker J.A., Van Dijk K.R., et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011, 134:1635-1646.
75. Klunk W.E., Price J.C., Mathis C.A., et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007, 27:6174-6184.
76. Villemagne V.L., Ataka S., Mizuno T., et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009, 66:1537-1544.
77. Engler H., Forsberg A., Almkvist O., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
78. Jack C.R., Lowe V.J., Weigand S.D., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
79. Villain N., Chetelat G., Grassiot B., et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139.
80. Villemagne V.L., Pike K.E., Chetelat G., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
81. Vlassenko A.G., Mintun M.A., Xiong C., et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011, 70:857-861.
82. Bacskai B.J., Frosch M.P., Freeman S.H., et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007, 64:431-434.
83. Burack M.A., Hartlein J., Flores H.P., et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74:77-84.
84. Kadir A., Marutle A., Gonzalez D., et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011, 134:301-317.
85. Leinonen V., Alafuzoff I., Aalto S., et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008, 65:1304-1309.
86. Sabbagh M.N., Fleisher A., Chen K., et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Arch Neurol 2011, 68:1461-1466.
87. Sojkova J., Driscoll I., Iacono D., et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011, 68:232-240.
88. Villemagne V.L., McLean C.A., Reardon K., et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009, 80:998-1001.
89. Arnold S.E., Han L.Y., Clark C.M., et al. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 2000, 21:913-919.
90. Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
91. Schöll M., Almqvist O., Graff C., et al. Amyloid imaging in members of a family harbouring the Arctic mutation. Alzheimers Dement 2011, 7(Suppl 1):303.
92. Tomiyama T., Nagata T., Shimada H., et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63:377-387.
93. Cairns N.J., Ikonomovic M.D., Benzinger T., et al. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009, 66:1557-1562.
94. Ikonomovic M.D., Abrahamson E.E., Price J.C., et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012, 123:433-447.
95. Aizenstein H.J., Nebes R.D., Saxton J.A., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
96. Mormino E.C., Kluth J.T., Madison C.M., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
97. Reiman E.M., Chen K., Liu X., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106:6820-6825.
98. Rowe C.C., Ellis K.A., Rimajova M., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
99. Davies L., Wolska B., Hilbich C., et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988, 38:1688-1693.
100. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001, 17:101-118.
101. Pike K.E., Ellis K.A., Villemagne V.L., et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 2011, 49:2384-2390.
102. Sperling R.A., Johnson K.A., Doraiswamy P.M., et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013, 34:822-831.
103. Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240-246.
104. Petersen R.C., Smith G.E., Ivnik R.J., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995, 273:1274-1278.
105. Forsberg A., Engler H., Almkvist O., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465.
106. Kemppainen N.M., Aalto S., Wilson I.A., et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
107. Lowe V.J., Kemp B.J., Jack C.R., et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009, 50:878-886.
108. Pike K.E., Savage G., Villemagne V.L., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
109. Rentz D.M., Locascio J.J., Becker J.A., et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010, 67:353-364.
110. Roe C.M., Mintun M.A., D'Angelo G., et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008, 65:1467-1471.
111. Cohen A.D., Price J.C., Weissfeld L.A., et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009, 29:14770-14778.
112. Furst A.J., Rabinovici G.D., Rostomian A.H., et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging 2012, 33:215-225.
113. Resnick S.M., Sojkova J., Zhou Y., et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010, 74:807-815.
114. Villemagne V.L., Pike K.E., Darby D., et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008, 46:1688-1697.
115. Doraiswamy P.M., Sperling R.A., Coleman R.E., et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
116. Morris J.C., Roe C.M., Grant E.A., et al. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475.
117. Nordberg A., Carter S.F., Rinne J., et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012, 10.1007/s00259-012-2237-2.
118. Okello A., Koivunen J., Edison P., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760.
119. Wolk D.A., Price J.C., Saxton J.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65:557-568.
120. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111cm133.
121. Chetelat G., Villemagne V.L., Pike K.E., et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358.
122. Tucker A.M., Stern Y. Cognitive reserve in aging. Curr Alzheimer Res 2011, 8:354-360.
123. Ng S., Villemagne V.L., Berlangieri S., et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007, 48:547-552.
124. Rabinovici G.D., Rosen H.J., Alkalay A., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011, 77:2034-2042.
125. DeKosky S.T., Ikonomovic M.D., Styren S.D., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51:145-155.
126. Ikonomovic M.D., Abrahamson E.E., Isanski B.A., et al. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 2007, 64:1312-1317.
127. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995, 9:6-16.
128. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 2011, 77:39-47.
129. Blennow K., Zetterberg H., Minthon L., et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007, 419:18-22.
130. de Leon M.J., Mosconi L., Blennow K., et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007, 1097:114-145.
131. Hansson O., Zetterberg H., Buchhave P., et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 23:316-320.
132. Mattsson N., Andreasson U., Persson S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011, 7:386-395.e6.
133. Forsberg A., Almkvist O., Engler H., et al. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010, 7:56-66.
134. Tolboom N., van der Flier W.M., Yaqub M., et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009, 50:1464-1470.
135. Fagan A.M., Mintun M.A., Shah A.R., et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009, 1:371-380.
136. Fagan A.M., Roe C.M., Xiong C., et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349.
137. Grimmer T., Riemenschneider M., Forstl H., et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009, 65:927-934.
138. Koivunen J., Pirttila T., Kemppainen N., et al. PET Amyloid Ligand [C]PIB Uptake and Cerebrospinal Fluid beta-Amyloid in Mild Cognitive Impairment. Dement Geriatr Cogn Disord 2008, 26:378-383.
139. Apostolova L.G., Hwang K.S., Andrawis J.P., et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010, 31:1284-1303.
140. Shaw L.M., Korecka M., Clark C.M., et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007, 6:295-303.
141. Frisoni G.B., Fox N.C., Jack C.R., et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6:67-77.
142. Archer H.A., Edison P., Brooks D.J., et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006, 60:145-147.
143. Becker J.A., Hedden T., Carmasin J., et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69:1032-1042.
144. Bourgeat P., Chetelat G., Villemagne V.L., et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127.
145. Chetelat G., Villemagne V.L., Bourgeat P., et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010, 67:317-324.
146. Tosun D., Schuff N., Mathis C.A., et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 2011, 134:1077-1088.
147. Forster S., Grimmer T., Miederer I., et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012, 71:792-797.
148. Chetelat G., Villemagne V.L., Villain N., et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012, 78:477-484.
149. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
150. Berg L., McKeel D.W., Miller J.P., et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998, 55:326-335.
151. Rabinovici G.D., Furst A.J., Alkalay A., et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010, 133:512-528.
152. Bateman R.J., Xiong C., Benzinger T.L., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
153. Landt J., D'Abrera J.C., Holland A.J., et al. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar beta-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch Neurol 2011, 68:890-896.
154. Villemagne V.L., Pike K., Pejoska S., et al. 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. J Alzheimers Dis 2010, 19:423-428.
155. Gomperts S.N., Rentz D.M., Moran E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
156. Maetzler W., Liepelt I., Reimold M., et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009, 34:107-112.
157. Johnson K.A., Gregas M., Becker J.A., et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007, 62:229-234.
158. Drzezga A., Grimmer T., Henriksen G., et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008, 39:619-633.
159. Engler H., Santillo A.F., Wang S.X., et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 2008, 35:100-106.
160. Pletnikova O., West N., Lee M.K., et al. Abeta deposition is associated with enhanced cortical a-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005, 26:1183-1192.
161. Masliah E., Rockenstein E., Veinbergs I., et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:12245-12250.
162. Halliday G., Hely M., Reid W., et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008, 115:409-415.
163. Rabinovici G.D., Miller B.L. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010, 24:375-398.
164. Leyton C.E., Villemagne V.L., Savage S., et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 2011, 134:3030-3043.
165. Rabinovici G.D., Jagust W.J., Furst A.J., et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008, 64:388-401.